Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 2NIH 2NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 12Neoplasms, Plasma Cell 2Waldenstrom Macroglobulinemia 1Recurrence 1Melanoma 1Lymphoma 1Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 50Vincristine 49Doxorubicin 44Prednisone 42Rituximab 32Radiotherapy 27Etoposide 27Methotrexate 24Filgrastim 24Cytarabine 23Dexamethasone 15Granulocyte Colony-Stimulating Factor 13Bleomycin 13Vinblastine 12Peripheral Blood Stem Cell Transplantation 12Leucovorin 11Gene Expression Profiling 10Bortezomib 10Immunohistochemistry 9Procarbazine 8Polymerase Chain Reaction 8Gemcitabine 8Melphalan 7Amplified Fragment Length Polymorphism Analysis 7VAP-cyclo protocol 6Mercaptopurine 6Ifosfamide 6Dacarbazine 6Carmustine 6Microarray Analysis 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Lymphoma × Thalidomide × Clear all
NCT00723658 2015-03-06

S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

SWOG Cancer Research Network

Phase 2 Withdrawn
Lymphoid

Lymphoma, Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡